TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06031844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: oral film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: oral film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: oral film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral film-coated tablets
Study: NCT06529978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreMap EP Mapping System Mapping
Description: Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreMap EP Mapping System Mapping
Description: Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreMap EP Mapping System Map-Guided Ablation
Description: Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
Study: NCT04995081

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological/Vaccine: Allogeneic HB-adMSCs
Description: HB-adMSCs will be administered intravenously to study participants who qualify.
Study: NCT06282952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fecal transplant
Description: At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplant
Description: At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
Study: NCT05972122

Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesia management; group S and C
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT04812236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wulingsan single decoction granules
Description: Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Study: NCT05004909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% Tretinoin
Description: Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
Study: NCT04995081

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological/Vaccine: Allogeneic HB-adMSCs
Description: HB-adMSCs will be administered intravenously to study participants who qualify.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sterile Saline Solution 0.9%
Study: NCT04812236

Intervention type: DRUG
Group type: OTHER
Intervention: Wulingsan co-decoction granules
Description: Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water

Intervention type: DRUG
Group type: OTHER
Intervention: Wuling Powder
Description: Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wulingsan granule simulant
Description: Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Study: NCT00992615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: prostate cores - 12 or 20

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: prostate cores - 12 or 20
Study: NCT04995081

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Saline Solution 0.9%
Study: NCT06150417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor signaling inhibitor (ARSI)
Description: Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen receptor signaling inhibitor (ARSI)
Description: Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
Study: NCT04726566

Intervention type: PROCEDURE
Intervention: Tendon graft
Description: Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft

Intervention type: PROCEDURE
Intervention: Suture with biological reinforcement
Description: Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
Study: NCT05451160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steep pulse therapy system
Description: The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF Ablation System
Description: RF Ablation System
Study: NCT05673382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy
Description: The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
Study: NCT06150417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
Description: Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
Description: Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastasis directed radiotherapy (MDRT)
Description: In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
Study: NCT05690230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental changes
Description: A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
Study: NCT04359784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given IV (previously SC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05357586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
Study: NCT05162833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraNova Neuromodulation Device
Description: TENS device
Study: NCT05212623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent influenza split vaccine
Description: This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent influenza split vaccine
Description: This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus split vaccine
Description: This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Study: NCT04359784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo BMA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05212623

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus split vaccine
Description: This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
Study: NCT05516264

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dog visits/control visits
Description: See arm description above

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control visits/dog visits
Description: See arm description above
Study: NCT04493229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: IM Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo IM
Study: NCT04726124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation Therapeutic Apparatus
Description: The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation Therapeutic Apparatus
Description: The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
Study: NCT04849260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec combined with ZKAB001
Description: 1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZKAB001 monotherapy
Description: ZKAB001 monotherapy
Study: NCT05261594

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine
Description: Caffeine capsule 150 mg, oral intake

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine
Description: Caffeine capsule 150 mg, oral intake

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo capsule, oral intake

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo capsule, oral intake
Study: NCT04825379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioactive composite
Description: Cention N
Study: NCT05569057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1811-03
Description: SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
Study: NCT03650101

Intervention type: PROCEDURE
Intervention: ETV/CPC
Description: The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
Study: NCT04825379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: posterior composite
Description: G-ænial Posterior
Study: NCT06507345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]
Description: In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]
Description: Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
Study: NCT04922814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: muscle relaxation
Description: They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
Study: NCT06642402

Intervention type: DIAGNOSTIC_TEST
Intervention: Kidney biopsy
Description: Patient refered to kidney biopsy independent of the presented study

Intervention type: DIAGNOSTIC_TEST
Intervention: Kidney biopsy
Description: Patient refered to kidney biopsy independent of the presented study

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary extracellular vesicle testing
Description: Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
Study: NCT06231251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: upper gastrointestinal endoscopy
Description: reduction of ghrelin rich gastric mucosa with band ligation or argon plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: upper gastrointestinal endoscopy
Description: reduction of ghrelin rich gastric mucosa with band ligation or argon plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: upper gastrointestinal endoscopy
Description: reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
Study: NCT05444829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: specific screw holes locating surgical guide and pre-bent plates
Description: Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.

Intervention type: DEVICE
Group type: OTHER
Intervention: classical reduction and internal fixation.
Description: mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
Study: NCT06091202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CORPs Intervention
Description: Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up.
Study: NCT06642402

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary extracellular vesicle testing
Description: Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary extracellular vesicle testing
Description: Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary extracellular vesicle testing
Description: Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
Study: NCT06091202

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEUC)
Description: Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up.
Study: NCT06642402

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmunity in plasma
Description: Expected autoimmunity in plasma isolated from blood samples
Study: NCT05859373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation
Description: TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation
Description: TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
Study: NCT04801823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home introduction
Description: Cautious, graded introduction of individual tree nuts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi Nut oral food challenge
Description: In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
Study: NCT05685511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Optimization
Description: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Study: NCT05859373

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450 injection, sequential or concurrent chemoradiation
Description: TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
Study: NCT06464146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: oral morphine (0.5 mg / kg)